Changes in Beneficial Ownership · 4
Artiva Biotherapeutics, Inc.
ARTVNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-10
- Issuer
- Artiva Biotherapeutics, Inc.
- Issuer CIK
- 0001817241
- Trading symbol
- ARTV
Reporting owner 1
- Name
- MOORE ALISON
- Reporting owner CIK
- 0001754937
- Relationship
- Director
- Address
- C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO, CA, 92121
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy) | 10.42 | 2026-09-10 | A · Form 4 | 16,250 | A | 0 | [F1] | 2036-09-09 | Common Stock | 16,250 | 16,250 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.↩ 1
Signature 1
- Signed
- /s/ Jennifer Bush, Attorney-in-Fact
- Date
- 2026-09-14
Company context
Artiva is a clinical-stage biotechnology company that has focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases. AlloNK® (AB-101), the Company’s lead development candidate, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy that was evaluated in combination with B-cell-targeted monoclonal antibodies. On October 27, 2026, Artiva announced the discontinuation of further clinical development of AlloNK and the initiation of an evaluation of strategic alternatives. Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.